On the other hand, KRAS G12C inhibitors do not provide as durable responses as tyrosine kinase inhibitors against EGFR or ALK; the median progression-free survival times of NSCLC patients treated with sotorasib and the EGFR-tyrosine kinase inhibitor (EGFR-TKI) osimertinib were 6.8 months [13] and 18.9 months [14], respectively. Here, KRAS is linked to non-small cell lung carcinoma.